1. The relationship of Fc?RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
2. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
3. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
4. Long‑Term Efficacy of Ocrelizumab up to 8 Years in RMS Patients in the OPERA Study and Open‑Label Extension Using Repeated Event Analysis;Bermel;Presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC); May 31-June,2023
5. Long‑Term Treatment With First‑Line Ocrelizumab in Patients With Early RMS: 9-Year Follow‑Up Data From the OPERA Trial, Presented at the 75th Annual Meeting of the American Academy of Neurology (AAN);Cerqueira JJ;April,2011